Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ABHD6 | Q9BV23 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366408 | 0.92 | ESR1 (0.52) | ESR1ESR2PKMHDAC6HDAC8 | |
| SCHEMBL1366031 | 0.89 | ESR1 (0.48) | ESR1ESR2PKMHDAC6HDAC8 | |
| SCHEMBL1367533 | 0.87 | ESR1 (0.64) | ESR1ESR2PKMHDAC6HDAC8 | |
| SCHEMBL3292015 | 0.87 | ESR1 (0.64) | ESR1ESR2PKMHDAC6HDAC8 | |
| Hydrochloric Acid SCHEMBL6193455 | 0.85 | ESR1 (0.61) | ESR1ESR2PKMHDAC6HDAC8 | |
| SCHEMBL5418343 | 0.85 | ESR1 (0.61) | ESR1ESR2PKMHDAC6HDAC8 | |
| SCHEMBL14101079 | 0.84 | ESR1 (0.70) | ESR1ESR2PKMHDAC6HDAC8 | |
| SCHEMBL31670429 | 0.83 | ESR1 (0.68) | ESR1ESR2PKMHDAC6HDAC8 | |
| SCHEMBL4704441 | 0.83 | ESR1 (0.68) | ESR1ESR2PKMHDAC6HDAC8 | |
| SCHEMBL28631452 | 0.82 | ESR1 (0.57) | ESR1ESR2PKMHDAC6HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173648-B2 | 1,2,3,4-tetrahydroisoquinoline derivatives, preparation process therefor and pharmaceutical composition containing the same | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-05-08 | — | — | US | claimed |
| US-20100016309-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparation Process therefor and Pharmaceutical Composition Containing the Same | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-01-21 | — | — | US | claimed |
| EP-2069327-B1 | NEW PYRIDONE DERIVATIVES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INT (DE) | 2013-10-16 | — | — | EP | disclosed |
| US-8173648-B2 | 1,2,3,4-tetrahydroisoquinoline derivatives, preparation process therefor and pharmaceutical composition containing the same | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2012-05-08 | — | — | US | disclosed |
| US-20120010185-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | US | disclosed |
| US-8067590-B2 | Melanin-concentrating hormone (MCH) receptor antagonists; treating obesity, eating disorders, affective disorders, drug dependency; compounds are amino-functional pyridazin-3-one, 1H-pyridin-2-one or 3H-pyrimidin-4-one | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| EP-2383259-A1 | New pyridone derivatives with MCH antagonistic activity and medicaments comprising these compounds | Boehringer Ingelheim International GmbH (DE) | 2011-11-02 | — | — | EP | disclosed |
| US-20100016309-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparation Process therefor and Pharmaceutical Composition Containing the Same | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-01-21 | — | — | US | disclosed |
| US-20100016309-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparation Process therefor and Pharmaceutical Composition Containing the Same | NATIONAL DEFENSE MEDICAL CENTER (TW) | 2010-01-21 | — | — | US | disclosed |
| WO-2009103478-A1 | PYRIDONE AND PYRIDAZINONE DERIVATIVES AS MCH ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-27 | — | — | WO | disclosed |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| EP-1701954-A1 | N-SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066165-A1 | N-SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010185-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | ESR1 2249/4885ESR2 1432/4885PKM 230/4885 |
| US-20080255083-A1 | NEW PYRIDONE DERIVATES WITH MCH ANTAGONISTIC ACTIVITY AND MEDICAMENTS COMPRISING THESE COMPOUNDS | MCHR1, MCHR2, GPR119 | ESR1 2249/4885ESR2 1432/4885PKM 230/4885 |
| US-20100016309-A1 | 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparation Process therefor and Pharmaceutical Composition Containing the Same | APP, BACE1, PSEN1 | ESR1 2972/4885ESR2 3287/4885PKM 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.